This is a demo store. No orders will be fulfilled.

Enoticumab (anti-DLL4) - Primary antibody, specific to DLL4, Human IgG1, INHIBITOR of Delta-like protein 4 inhibitor, INHIBITOR of Delta-like protein 4 inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Human
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab183454
Grouped product items
SKU Size
Availability
Price Qty
Ab183454-100μg
100μg
10
$109.90
Ab183454-1mg
1mg
4
$519.90
Ab183454-5mg
5mg
1
$1,299.90
Ab183454-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,079.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Enoticumab (anti-DLL4) - Primary antibody, specific to DLL4, Human IgG1, INHIBITOR of Delta-like protein 4 inhibitor
Synonyms AOS6 antibody | Delta 4 antibody | delta 4 precursor antibody | Delta ligand 4 antibody | delta ligand 4 precursor antibody | Delta like 4 antibody | Delta like 4 homolog antibody | Delta like 4 protein antibody | Delta like canonical Notch ligand 4 antib
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity DLL4
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Delta-like protein 4 inhibitor
Product Description

Enoticumab (anti-DLL4) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab (anti-DLL4) in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.4 kDa (Light Chain) & 53.7 kDa (Heavy Chain), under reducing conditions; 212.6 kDa, under non-reducing conditions.
Purification Method Protein A purified
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 1192578-27-0

Associated Targets(Human)

DLL4 Tbio Delta-like protein 4 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Enoticumab (anti-DLL4) (Ab183454) - ELISA
Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Enoticumab (anti-DLL4) (Ab183454) with the EC₅₀ of 19.84 ng/mL.

Enoticumab (anti-DLL4) (Ab183454) - ELISA
Immobilized HuDLL4-ECD-his at 2.0 μg/mL can bind Enoticumab (anti-DLL4) (Ab183454) with the EC₅₀ of 2.33 ng/mL.

Enoticumab (anti-DLL4) (Ab183454) - SEC
The purity of Enoticumab (anti-DLL4) (Ab183454) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0708680 Certificate of Analysis Jul 24, 2024 Ab183454
ZJ24F0708679 Certificate of Analysis Jul 24, 2024 Ab183454
ZJ24F0708678 Certificate of Analysis Jul 24, 2024 Ab183454

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.